T2Resistance - Detection of Resistance Related Genes

Resistance Bacterial Clinical Trial

Official title:

T2Resistance 510(k) Study Protocol - Detection and Identification of Several Classes of Resistance Genes in Both Gram-positive and Gram-negative Pathogens

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05231187
• Other study ID #: 210-11147
• Status: Active, not recruiting
• Start date: January 10, 2022
• Est. completion date: November 2023

Study information

• Verified date: September 2023
• Source: T2 Biosystems
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of the T2Resistance Panel by validating clinical performance in three study arms: 1. Prospective arm: positive percent agreement (PPA) and negative percent agreement (NPA) against genetic determinants of resistance detected in whole blood clinical samples or isolates collected from positive blood cultures prospectively collected clinical samples of whole blood. 2. Contrived arm: positive percent agreement (PPA) and negative percent agreement (NPA) against samples with known status, via spiking healthy whole blood samples with bacterial strains harboring the resistance gene targets on the T2Resistance Panel. 3. Healthy donor arm: negative percent agreement (NPA) with presumed negativity of healthy donor whole blood samples. The data from all arms of the study will be used to support the Premarket Notification for the T2Resistance Panel to the U.S. Food and Drug Administration. Primary Endpoints The primary endpoints of this study with the T2Resistance Panel are estimated sensitivity, specificity, and safety.

Description:

The purpose of this study is to evaluate the safety and effectiveness of the T2Resistance Panel by validating clinical performance in three study arms: 1. Prospective arm: positive percent agreement (PPA) and negative percent agreement (NPA) against genetic determinants of resistance detected in whole blood clinical samples or isolates collected from positive blood cultures prospectively collected clinical samples of whole blood. 2. Contrived arm: positive percent agreement (PPA) and negative percent agreement (NPA) against samples with known status, via spiking healthy whole blood samples with bacterial strains harboring the resistance gene targets on the T2Resistance Panel. 3. Healthy donor arm: negative percent agreement (NPA) with presumed negativity of healthy donor whole blood samples. The data from all arms of the study will be used to support the Premarket Notification for the T2Resistance Panel to the U.S. Food and Drug Administration. Primary Endpoints The primary endpoints of this study with the T2Resistance Panel are estimated sensitivity, specificity, and safety. Sensitivity The estimated sensitivity of the T2Resistance Panel will be derived from two metrics: 1. Prospective arm: positive concordance between a positive result on the T2Resistance Panel and a positive sequencing result from a whole blood sample or isolate from positive blood culture 2. Contrived arm: positive concordance between a positive result on the T2Resistance Panel and a sample spiked with a bacterial isolates sequence confirmed to be harboring a known resistance gene on the T2Resistance Panel. The Contrived arm of the study will consist of ≥ 350 whole blood samples spiked with titer levels ranging from < 1 CFU/mL to 100 CFU/mL. These samples will be provided to selected test sites for testing. Sensitivity values will be calculated separately for each channel and study arm, e.g., Prospective and Contrived study arms for blaKPC, blaCTX-M, blaNDM / blaVIM / blaIMP, blaOXA-48 Group, vanA / vanB, mecA / mecC and AmpC (blaCMY / blaDHA) channels. Specificity The estimated specificity of the T2Resistance Panel will be derived from three metrics: 1. Prospective arm: negative concordance between a negative ("Target not Detected") result on the T2Resistance Panel and a negative sequencing result from whole blood sample or isolate from positive blood culture 2. Healthy donor arm: negative concordance between a negative ("Target not Detected") result on the T2Resistance Panel and a presumed negativity of healthy donor whole blood sample 3. Contrived arm: negative concordance between a negative ("Target not Detected") result in a given channel of the T2Resistance Panel and the presence of a spiked bacteria known to not harbor the given resistance gene on the T2Resistance Panel Specificity values will be calculated separately for each channel and study arm, e.g., Prospective, Healthy donor, and Contrived study arms for blaKPC, blaCTX-M, blaNDM / blaVIM / blaIMP, blaOXA-48 Group, vanA / vanB, mecA / mecC and AmpC (blaCMY / blaDHA) channels. Safety There are no expected adverse events that are directly related to the T2Resistance Panel and the T2Dx Instrument as a result of participating in this study. Since the device does not come in contact with the patients and the test results are not used in clinical practice as part of standard of care, the only adverse events associated with study participation is the collection of blood samples for T2Resistance Panel testing.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1300
• Est. completion date: November 2023
• Est. primary completion date: November 2023
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Prospective Arm:

• Obtain informed consent according to institutional requirements, as needed.
• Patient has had a diagnostic blood culture ordered per routine standard of care.
• Patient is 18 years of age or older. Exclusion Criteria: Prospective Arm
• Patient has other co-morbid condition(s) that, in the opinion of the Investigator, could limit the patient's ability to participate in the study or impact the scientific integrity of the study.
• Patient has had previous specimens tested for the T2Resistance Panel with valid results.

Related Conditions & MeSH terms

• Resistance Bacterial

Intervention

Diagnostic Test:
• T2Resistance Panel
The T2Resistance Panel is an in vitro diagnostic medical device that runs on the T2Dx instrument and detects bacterial markers that are commonly associated with antibiotic resistance. T2Resistance Panel detects thirteen (13) markers of resistance in seven detection channels: blaKPC blaCTX-M blaNDM / blaVIM / blaIMP blaOXA-48 Group vanA / vanB mecA / mecC AmpC (blaCMY / blaDHA)

Locations

Country	Name	City	State
United States	Johns Hopkins University	Baltimore	Maryland
United States	University of Alabama at Birmingham	Birmingham	Alabama
United States	New York University Langone Health	Brooklyn	New York
United States	University of Texas Health Science Center	Houston	Texas
United States	University Health, Truman Medical Center	Kansas City	Missouri
United States	Ochsner Medical Center	New Orleans	Louisiana
United States	University of Pittsburgh	Pittsburgh	Pennsylvania
United States	Rhode Island Hospital	Providence	Rhode Island
United States	Zuckerberg San Francisco General Hospital	San Francisco	California
United States	Tampa General Hospital	Tampa	Florida

Sponsors (2)

Lead Sponsor	Collaborator
T2 Biosystems	Biomedical Advanced Research and Development Authority

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity - Prospective	Positive concordance between positive T2Resistance panel results for positive samples.	Six months from collection, maximum.
Primary	Specificity - Prospective	Negative concordance between a negative ("Target not Detected") result on the T2Resistance Panel and a negative sequencing result or a known negative sample.	Six months from collection, maximum.
Primary	Safety / Adverse Events	Potential adverse events associated with the collection of blood samples for T2Resistance Panel Testing.	During patient blood draw or immediately after blood draw, typically <1 hour.
Secondary	Sensitivity - Contrived	Concordance between T2Resistance Panel results and positive blood culture, and contrived samples.	Six months from collection, maximum.
Secondary	Specificity - Contrived	Concordance between a negative ("Target not Detected") result on the T2Resistance Panel and sensitivity results associated with antibiotic susceptibility testing from positive blood culture samples or positive contrived samples.	Six months from collection, maximum.